comparemela.com

Latest Breaking News On - Nasdaq lixt - Page 1 : comparemela.com

Short Interest in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Decreases By 28.7%

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT – Get Free Report) saw a large decrease in short interest in June. As of June 30th, there was short interest totalling 8,700 shares, a decrease of 28.7% from the June 15th total of 12,200 shares. Based on an average trading volume of 20,700 shares, the short-interest ratio is presently […]

Nasdaq
Geode-capital-management
Ep-wealth-advisors
Lixte-biotechnology-holdings-inc
Ethos-financial-group
Lixte-biotechnology-company-profile
Renaissance-technologies
Lixte-biotechnology-holdings
Get-free-report
Biotechnology-stock-down
Lixte-biotechnology

Lixte Biotechnology (LIXT) & Its Rivals Head to Head Comparison

Lixte Biotechnology (NASDAQ:LIXT – Get Rating) is one of 941 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Lixte Biotechnology to similar businesses based on the strength of its profitability, earnings, dividends, institutional ownership, valuation, analyst recommendations and risk. Insider and Institutional Ownership 8.8% of […]

California
United-states
Netherlands
Spain
Spanish
Loncode-institute
Research-institute-hospital-inc
Spanish-sarcoma-group
Netherlands-cancer-institute
Moffitt-cancer-center
Lixte-biotechnology-holdings-inc

Contrasting Lixte Biotechnology (LIXT) and Its Competitors

Lixte Biotechnology (NASDAQ:LIXT – Get Rating) is one of 941 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Lixte Biotechnology to related companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, risk and profitability. Analyst Ratings This is […]

California
United-states
Netherlands
Spain
Spanish
Loncode-institute
Research-institute-hospital-inc
Spanish-sarcoma-group
Netherlands-cancer-institute
Moffitt-cancer-center
Lixte-biotechnology-holdings-inc

LIXTE Biotechnology Announces the Closing of $5.8 Million

PASADENA, CA, April 14, 2022 (GLOBE NEWSWIRE) LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing.

United-states
Los-angeles
Exchange-commission
Westpark-capital-inc
Biotechnology-holdings-inc
Securities-exchange
Wallachbeth-capital
Nasdaq
Spark-capital
Westpark-capital
Jason-stern
Biotechnology-holdings

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Down 59.2% in March

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT – Get Rating) was the recipient of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 15,500 shares, a decline of 59.2% from the February 28th total of 38,000 shares. Currently, 0.3% of the shares of the company are […]

Morgan-stanley
Geode-capital-management
Lixte-biotechnology-company-profile-get-rating
Renaissance-technologies
Lixte-biotechnology-holdings-inc
Nasdaq
Vanguard-group-inc
Lixte-biotechnology-holdings
Get-rating
Lixte-biotechnology
Capital-management

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.